3,4-diaminopyridine for the treatment of Lambert–Eaton myasthenic syndrome

References

• Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am. J. Physiol.187, 612–613 (1956).
   Web of Science ®Google Scholar
• O’Neill JH, Murray NM, Newsom-Davis J. The Lambert–Eaton myasthenic syndrome. A review of 50 cases. Brain111, 577–596 (1988).
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert–Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve32, 226–229 (2005).
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Wirtz PW, Kuks JB et al. The Lambert–Eaton myasthenic syndrome 1988–2008: a clinical picture in 97 patients. J. Neuroimmunol.15, 201–202 (2008).
   Google Scholar
• Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton–Lambert) syndrome. Lancet2, 224–226 (1981).
   PubMed Web of Science ®Google Scholar
• Prior C, Lang B, Wray D, Newsom-Davis J. Action of Lambert–Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann. Neurol.17, 587–592 (1985).
   PubMed Web of Science ®Google Scholar
• Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B. The action of Lambert–Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve25, 715–724 (2002).
   PubMed Web of Science ®Google Scholar
• AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert–Eaton myasthenic syndrome: summary statement. Muscle Nerve24, 1236–1238 (2001).
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Demirci M, Kim DS et al. Postexercise facilitation of reflexes is not common in Lambert–Eaton myasthenic syndrome. Neurology59, 1085–1087 (2002).
   PubMed Web of Science ®Google Scholar
• Wirtz PW, van Dijk JG, van Doorn PA et al. The epidemiology of the Lambert–Eaton myasthenic syndrome in The Netherlands. Neurology63, 397–398 (2004).
   PubMed Web of Science ®Google Scholar
• Tim RW, Massey JM, Sanders DB. Lambert–Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology54, 2176–2178 (2000).
   PubMed Web of Science ®Google Scholar
• Nakao YK, Motomura M, Fukudome T et al. Seronegative Lambert–Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology59, 1773–1775 (2002).
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert–Eaton myasthenic syndrome. J. Clin. Oncol.26, 4276–4281 (2008).
   PubMed Web of Science ®Google Scholar
• Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert–Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet353, 117–118 (1999).
   PubMed Web of Science ®Google Scholar
• Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert–Eaton myasthenic syndrome with and without associated lung carcinoma. Hum. Immunol.14, 29–36 (1985).
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Roep BO, Schreuder GM et al. HLA class I and II in Lambert–Eaton myasthenic syndrome without associated tumor. Hum. Immunol.62, 809–813 (2001).
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Willcox N, van der Slik AR et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome. J. Neuroimmunol.159, 230–237 (2005).
   PubMed Web of Science ®Google Scholar
• Clamon GH, Evans WK, Shepherd FA, Humphrey JG. Myasthenic syndrome and small cell cancer of the lung. Variable response to antineoplastic therapy. Arch. Intern. Med.144, 999–1000 (1984).
   PubMedGoogle Scholar
• Chalk CH, Murray NM, Newsom-Davis J, O’Neill JH, Spiro SG. Response of the Lambert–Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology40, 1552–1556 (1990).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert–Eaton myasthenic syndrome. Neurology34, 480–485 (1984).
   PubMed Web of Science ®Google Scholar
• Bain PG, Motomura M, Newsom-Davis J et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology47, 678–683 (1996).
   PubMed Web of Science ®Google Scholar
• Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton–Lambert syndrome. Ann. Neurol.11, 570–575 (1982).
   PubMed Web of Science ®Google Scholar
• Lambert EH. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann. NY Acad. Sci.135, 367–384 (1966).
   PubMed Web of Science ®Google Scholar
• Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology31, 265–271 (1981).
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert–Eaton myasthenic syndrome. N. Engl. J. Med.321, 1567–1571 (1989).
   PubMed Web of Science ®Google Scholar
• Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome. Neurology54, 603–607 (2000).
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Verschuuren JJ, van Dijk JG et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin. Pharmacol. Ther.86, 44–48 (2009).
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve40, 795–800 (2009).
   PubMed Web of Science ®Google Scholar
• Murray NMF, Newsom-Davis J, Karni Y, Wiles CM. Oral 3,4-diaminopyridine in the treatment of the Lambert–Eaton myasthenic syndrome (LEMS) [abstract]. J. Neurol. Neurosurg. Psychiatry47, 1052 (1984).
   Web of Science ®Google Scholar
• Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol.61, 25–34 (1980).
   PubMed Web of Science ®Google Scholar
• Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Ther.227, 260–265 (1983).
   PubMed Web of Science ®Google Scholar
• Kirsch GE, Narahashi T. 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys. J.22, 507–512 (1978).
   PubMed Web of Science ®Google Scholar
• Lemeignan M, Millart H, Lamiable D, Molgó J, Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res.304, 166–169 (1984).
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton–Lambert syndrome. J. Neurol. Neurosurg. Psychiatry46, 684–685 (1983).
   PubMed Web of Science ®Google Scholar
• Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst. Rev.2, CD001330 (2003).
   Google Scholar
• Vohra MM, Pradhan SN. Pharmacology of 3,4-diaminopyridine. Arch. Int. Pharmacodyn. Ther.150, 413–424 (1964).
   PubMedGoogle Scholar
• Lechat P, Deysson G, Lemeignan M, Adolphe M. [Toxicité aiguë composée de quelques aminopyridines in vivo (souris) et in vitro (cultures cellulaires)]. Ann. Pharm. Fr.26, 345–349 (1968).
   PubMed Web of Science ®Google Scholar
• Durant NN, Marshall IG. The effects of 3,4-diaminopyridine on spontaneous and evoked transmitter release at the frog neuromuscular junction (proceedings). J. Physiol.280, 21P (1978).
   PubMedGoogle Scholar
• Bever CT Jr, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann. Neurol.27, 421–427 (1990).
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann. NY Acad. Sci.841, 769–772 (1998).
   PubMed Web of Science ®Google Scholar
• Sanders DB. 3,4-Diaminopyridine (DAP) in the treatment of Lambert–Eaton myasthenic syndrome (LEMS). Ann. NY Acad. Sci.841, 811–816 (1998).
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Treatment of Lambert–Eaton myasthenic syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology34, 1324–1330 (1984).
   PubMed Web of Science ®Google Scholar
• Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert–Eaton myasthenic syndrome. J. Toxicol. Clin. Toxicol.33, 249–251 (1995).
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert–Eaton myasthenic syndrome. Acta Neurol. Scand.88, 136–140 (1993).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Anderson PA, Leslie J et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology47, 1457–1462 (1996).
   PubMed Web of Science ®Google Scholar
• Flet L, Polard E, Guillard O et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J. Neurol.57, 937–946 (2010).
   Google Scholar
• Skeie GO, Apostolski S, Evoli A et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders (EFNS Task Force article). Eur. J. Neurol.13, 691–699 (2006).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation. 3,4 diaminopyridine phosphate for the treatment of Lambert–Eaton myasthenic syndrome. EMA/COMP/2732/2002 Rev.3. EMA, London, UK (2010).
   Google Scholar
• Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert–Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve40, 305–308 (2009).
   PubMed Web of Science ®Google Scholar
• Maddison P, McConville J, Farrugia ME et al. The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry DOI: jnnp.2009.197632 (2010) (Epub ahead of print).
   PubMedGoogle Scholar